Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration

Feli M. Walther, Allan J. Paul, Mark J. Allan, Rainer Ka Roepke, Martin C. Nuernberger

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control after a single oral dose. This study investigated the safety of oral administration of fluralaner at 3 times the highest expected clinical dose to Multi Drug Resistance Protein 1 (MDR1(-/-)) gene defect Collies. Methods. Sixteen Collies homozygous for the MDR1 deletion mutation were included in the study. Eight Collies received fluralaner chewable tablets once at a dose of 168 mg/kg; eight sham dosed Collies served as controls. All Collies were clinically observed until 28 days following treatment. Results: No adverse events were observed subsequent to fluralaner treatment of MDR1(-/-) Collies at three times the highest expected clinical dose. Conclusions: Fluralaner chewable tablets are well tolerated in MDR1(-/-) Collies following oral administration.

    Original languageEnglish (US)
    Article number86
    JournalParasites and Vectors
    Volume7
    Issue number1
    DOIs
    StatePublished - Mar 6 2014

    Keywords

    • Bravecto™
    • Dog
    • Fluralaner
    • MDR1
    • Safety

    ASJC Scopus subject areas

    • Parasitology
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration'. Together they form a unique fingerprint.

    Cite this